Insmed (INSM) Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INSM shares.
View INSM analyst ratings or view top-rated stocks.

13 Wall Street research analysts have issued 12-month price targets for Insmed's stock. Their INSM share price forecasts range from $28.00 to $53.00. On average, they anticipate the company's stock price to reach $43.71 in the next twelve months. This suggests a possible upside of 67.0% from the stock's current price.
View analysts price targets for INSM or view top-rated stocks among Wall Street analysts.

Insmed's stock was trading at $19.98 on January 1st, 2023. Since then, INSM shares have increased by 31.0% and is now trading at $26.17.
View the best growth stocks for 2023 here.

Insmed saw a increase in short interest in August. As of August 31st, there was short interest totaling 12,440,000 shares, an increase of 11.9% from the August 15th total of 11,120,000 shares. Based on an average daily trading volume, of 1,230,000 shares, the days-to-cover ratio is currently 10.1 days.
View Insmed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our INSM earnings forecast.

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by $0.68. The biopharmaceutical company earned $77.23 million during the quarter, compared to analyst estimates of $70.23 million. Insmed had a negative trailing twelve-month return on equity of 3,789.32% and a negative net margin of 258.22%. The business's quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.80) EPS.

ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include BNY Mellon Innovators ETF (BKIV), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Principal Healthcare Innovators ETF (BTEC).

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (2.98%), Bellevue Group AG (2.30%), Suvretta Capital Management LLC (2.16%), Geode Capital Management LLC (1.88%), Alliancebernstein L.P. (1.76%) and Holocene Advisors LP (1.45%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends.

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INSM stock can currently be purchased for approximately $26.17.

Insmed (NASDAQ:INSM) has a market capitalization of $3.76 billion and generates $245.36 million in revenue each year. The biopharmaceutical company earns $-481,530,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis.

The company employs 373 workers across the globe.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.